Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... The North America Thermal Protective Clothing Market ... analysis of the growth trends and revenue forecasts. ... by 2018, growing at a CAGR of 7.1% ... TOC of the North America Thermal Protective Clothing ... in-depth analysis and industry segmentation supported by various ...
    (Date:11/26/2014)... On January, 14, 2015, UMBC’s ... D.C. science community to the UMBC campus for a ... the Protein Society, will take place from 9 a.m. ... Through discussion, presentations and workshops, the free symposium ... their role in the industry and the future of ...
    (Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) ... Alliance , provider of clinical research and data management ... addition to its CRO Partnership Program, Clinovo expands ... India. , “We have found Clinovo’s ClinCapture to ... platform which is both user friendly and easy to ...
    (Date:11/26/2014)... SoundConnect , an award winning unified communications ... Darren Suders has joined the team as Director of ... partner program through innovative offerings, consistent partner ... brings more than 10-years of channel telecommunication experience to ... from policy development, to partner education and to expansion. ...
    Breaking Biology Technology:The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2
    ... Eric Schmidt, then the CTO of Sun Microsystems, gave ... language called Java. A thoroughly modern development platform for ... Java promised to ease programming headaches, the biggest of ... another. , ,Today, we can debate whether Java ...
    ... believes in reincarnation - in the business sense. , ,What ... reiterations of his company, Paragon Development Systems, Inc. , ... with a very important streak intact - 19 consecutive years ... a memory chip broker that managed to survive 20 years ...
    ... Madison, Wis. - Gov. Jim Doyle ... million in state funds for the development of renewable ... - which includes tax credits, low-interest loans, and grants ... the sale of state bonds - would leverage an ...
    Cached Biology Technology:Java's undeniable impact on the Web 2Java's undeniable impact on the Web 3PDS survives with technological reinvention 2PDS survives with technological reinvention 3PDS survives with technological reinvention 4PDS survives with technological reinvention 5Doyle announces $80M renewable energy strategy 2Doyle announces $80M renewable energy strategy 3Doyle announces $80M renewable energy strategy 4
    (Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
    (Date:11/6/2014)... for a predator. Except when that predator runs so fast ... to its size, is the fastest creature on Earth. Some ... second (at about five miles per hour). The fastest human ... gold from the tiger beetle, a person would have to ... has a problem. At peak speeds, everything becomes a blur. ...
    (Date:11/4/2014)... University of Utah engineers developed the first room-temperature fuel ... electricity without needing to ignite the fuel. These new ... off-grid power and sensors. , A study of the ... Society journal ACS Catalysis . , Fuel cells ... a fuel and an oxygen-rich source such as air. ...
    Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Jet-fueled electricity at room temperature 2
    ... understand molecular mechanisms underlying various diseases, notably cancer, have ... of patients for the expression status of thousands of ... of each gene in the genome, measured as the ... Since each of the tens of thousands of genes ...
    ... essayist as we have."New York Times Book Review "Carl ... today. A Planet of Viruses is an important primer on ... other times shocking, and always accessible. Whether discussing the common ... oceans, or the world,s viral future as seen through our ...
    ... 5, 2011 In their eagerness to cut nitrogen ... of Mexico, people have often sought simple explanations for ... or farmers who apply too much fertilizer, which then ... research that examined phosphorus loading from all 1768 counties ...
    Cached Biology News:Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes 2Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes 3Medusa-structure of gene regulatory network: Dominance of transcription factors in cancer subtypes 4A planet of viruses 2Study probes sources of Mississippi River phosphorus 2Study probes sources of Mississippi River phosphorus 3
    Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
    Request Info...
    Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
    Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
    Biology Products: